Students of Dr. Xiaoyan Jiang, Andrew Wu and Ryan Yen (Collings Stevens Laboratory), along with a team of researchers, have published a paper in Leukemia Journal titled, "Identification of Multivariable microRNA and Clinical Biomarker Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis."
More info: The paper explores predicting responses to Imatinib Mesylate (imatinib), a key therapy for chronic myeloid leukemia (CML). Despite its effectiveness, patients often need lifelong treatment due to the risk of relapse. The team analyzed clinical data and miRNA expression in CD34+ CML cells from 80 patients, identifying 16 miRNAs associated with imatinib nonresponse. Combining these miRNAs with clinical parameters, they developed a predictive panel surpassing individual miRNA or clinical panels. This groundbreaking study offers valuable insights, potentially revolutionizing treatment plans and diagnostic panels for CML patients.